1 Title Page

2 Title: Apathy and Affective Symptoms Associated with Elevated Alzheimer's Disease

3 **Biomarkers**

4 Authors

Name	Affiliations (separated by	Title	Highest	Email
	semi colon)		qualification	
Matthew JY	Neuropsychiatry Centre,	Dr	MBBS	Matthew.Kang1@unimelb.edu.au
Kang	Royal Melbourne		(Hons),	
	Hospital; Department of		FRANZCP	
	Psychiatry, University of			
-	Melbourne			
Dhamidhu	Neuropsychiatry Centre,	Dr	MBChB	deratne@unimelb.edu.au
Eratne	Royal Melbourne		FRANZCP	
	Hospital; Department of			
	Psychiatry, University of			
	Melbourne		DI D	
Samantha	Neuropsychiatry Centre,	Associate	PhD,	Samantha.loi@unimelb.edu.au
M L01	Royal Melbourne	Professor	FRANZCP,	
	Hospital; Department of		MBB2	
	Malhourne			
Christs	National Againg Dasaarah	D ₂	DLD	abriete dan a Qunimalh adu au
Dong	Institute: Department of	Dr	PIID	christa.dang@unimeto.edu.au
Dalig	General Practice			
	University of Melbourne			
Alexander	Department of Clinical	A/Prof	MD	alexander.santillo@med.lu.se
F Santillo	Sciences, Faculty of	101101		
1 Sullino	Medicine, Lund University,			
	Malmö, Sweden			
Henrik	Department of Psychiatry	Prof	MD, PhD	henrik.zetterberg@gu.se
Zetterberg	and Neurochemistry,			
	Institute of Neuroscience			
	& Physiology,			
	Sahlgrenska Academy at			
	the University of			
	Gothenburg, Molndal,			
	Sweden.			
	Laboratory Sablaranaka			
	Laboratory, Samgrenska			
	Mölndəl Sweden			
	Department of			
	Neurodegenerative			
	Disease, Queen Square			

	Institute of Neurology, University College London, London, UK. UK Dementia Research Institute, University College London, London, UK. Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China. UW Department of Medicine, School of Medicine and Public Health, Madison, WI, USA.			
Kaj Blennow	Inst. of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden Clinical Neurochemistry Lab, Sahlgrenska University Hospital, Mölndal, Sweden Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, P.R. China	Proefssor	MD, PhD	kaj.blennow@neuro.gu.se
Philip B Mitchell	Discipline of Psychiatry and Mental Health, School of Clinical Medicine,	Scientia Professor	AM, FAHMS, FASSA,	Phil.mitchell@unsw.edu.au

	Faculty of Medicine and Health, UNSW		MBBS, MD, FRANZCP,	
			FRCPsych	
Malcolm	Department of Psychiatry,	Prof	MD,	mhopwood@unimelb.edu.au
Hopwood	University of Melbourne		FRANZCP	
	Professorial Psychiatry			
	Unit, Ramsay Clinic			
	Albert Road			
Charles B	Department of Medicine,	A/Prof	MPsych,	charles.malpas@unimelb.edu.au
Malpas^	Melbourne Medical		PhD	
	School, University of			
	Melbourne; Melbourne			
	School of Psychological			
	Sciences, University of			
	Melbourne			
Dennis	Neuropsychiatry Centre,	Professor	MBBS	Dennis.Velakoulis@mh.org.au
Velakoulis [^]	Royal Melbourne		DMedSci	
	Hospital; Department of		FRANZCP	
	Psychiatry, University of			
	Melbourne			

for the Alzheimer's Disease Neuroimaging Initiative*

*Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at:

https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf ^CB Malpas and D Velakoulis are joint senior authors

5 **Corresponding author:**

- 6 Dr Matthew Kang
- 7 MBBS BMEdSci MP FRANZCP
- 8 Neuropsychiatry Centre, Royal Melbourne Hospital, 300 Grattan St, Parkville VIC 3050,
- 9 Australia
- 10 matthew.kang1@unimelb.edu.au
- 11 Tel: +61 3 9342 8750
- 12

13 CRediT authorship contribution statement

Matthew JY Kang: Study conceptualisation, literature review, data analysis, manuscript writingand submission

16 Dhamidhu Eratne: Study design, data analysis, manuscript revision and supervision

- 17 Samantha M Loi manuscript revision and supervision
- 18 Christa Dang manuscript revision
- 19 Alexander F Santillo manuscript revision and supervision
- 20 Henrik Zetterberg: Study design, biomarker data generation, manuscript revision
- 21 Kaj Blennow: Study design, biomarker data generation, manuscript revision
- 22 Philip B Mitchell: Study design, supervision and manuscript revision
- 23 Malcolm Hopwood: Study design, supervision and manuscript revision
- Charles B Malpas: Study design, data analysis, statistical support, supervision and manuscript
 revision
- 26 Dennis Velakoulis: Study design, data analysis, supervision and manuscript revision

27

Word Count (excluding title page, abstract, headings, references, figures and tables): 2,998 words

- 30 Submission Type: Original Article
- 31 Abstract word count: 344
- 32 Number of figures: 2
- 33 Number of tables: 3
- 34

35 ORCID ID

- 36 Matthew Jee Yun Kang: https://orcid.org/0000-0001-9375-3762
- 37 Dhamidhu Eratne: https://orcid.org/0000-0002-3226-7645
- 38 Philip B. Mitchell 0000-0002-7954-5235
- 39 Dennis Velakoulis: https://orcid.org/0000-0002-8842-8479
- 40 Malcolm Hopwood: https://orcid.org/0000-0001-6004-4521
- 41 Henrik Zetterberg: 0000-0003-3930-4354
- 42 Christa Dang https://orcid.org/0000-0003-0905-282X
- 43 Alexander F Santillo ID 0000-0001-9717-0820
- 44 Samantha M Loi https://orcid.org/0000-0002-4953-4500

45

46 Acknowledgements

47 Data collection and sharing for the Alzheimer's Disease Neuroimaging Initiative (ADNI) is 48 funded by the National Institute on Aging (National Institutes of Health Grant U19AG024904). 49 The grantee organization is the Northern California Institute for Research and Education. In the 50 past, ADNI has also received funding from the National Institute of Biomedical Imaging and 51 Bioengineering, the Canadian Institutes of Health Research, and private sector contributions 52 through the Foundation for the National Institutes of Health (FNIH) including generous 53 contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug 54 Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol- Myers Squibb 55 Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and 56 Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; 57 Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & 58 Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; 59 Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; 60 Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; 61 Servier; Takeda Pharmaceutical Company; and Transition Therapeutics.

MK is supported by the Nick Christopher PhD scholarship and the Research Training Program
Scholarship from the Department of Psychiatry, University of Melbourne with contributions
from the Australian Commonwealth Government, and the Ramsay Hospital Research
Foundation.

A.F.S is primarily funded by the Swedish federal government under the ALF agreement (ALF
ALF 2022 YF 0017) The Fromma foundation and The Åke Wiberg foundation.

HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C,

74 #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-75 financed from the European Union's Horizon Europe Research and Innovation Programme and 76 by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure 77 Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen 78 Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), 79 the European Union's Horizon 2020 research and innovation programme under the Marie 80 Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme - Neurodegenerative Disease Research (JPND2021-00694), the National Institute 81 82 for Health and Care Research University College London Hospitals Biomedical Research Centre, 83 and the UK Dementia Research Institute at UCL (UKDRI-1003).

84 KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the 85 Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), 86 Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the 87 agreement between the Swedish government and the County Councils, the ALF-agreement 88 (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for 89 Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer's Association 2021 Zenith 90 Award (ZEN-21-848495), the Alzheimer's Association 2022-2025 Grant (SG-23-1038904 OC), 91 La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen 92 Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, Stockholm, Sweden.

93 PBM is supported by an Australian NHMRC Investigator Grant (1177991), Lansdowne
94 Foundation and Good Talk charity

- 95
- 96
- 97

98 Data Sharing Statement

99 This study used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI;100 adni.loni.usc.edu)

101 **Conflicts of interest**

102 HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, 103 Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito 104 Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, 105 Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, 106 Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by 107 Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, 108 and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of 109 the GU Ventures Incubator Program (outside submitted work).

KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.

117

118 SL has received honorarium from Lundbeck and Otsuka.

119

120 MH has served as a consultant and at advisory boards for Boehringer-Ingelheim, Cortexa, Eli 121 Lilly, Janssen, Lundbeck, Novartis, Otsuka, Orion, Servier and Takeda. He has received research

- 122 support from Alto Neuroscience, Boehringer-Ingelheim, Douglas, Janssen, and Lyndra,
- 123
- PBM has received honoraria from Janssen (Australia) for lectures and advisory boardmembership
- 126
- 127 The remaining authors declare no conflict of interests.

128 Key Points

Question: Do apathy and affective neuropsychiatric symptoms correlate with the rate of tau pathology and neurodegeneration, as measured by plasma phosphorylated-tau181 (p-tau181) and neurofilament light chain protein (NfL), in individuals across the clinical spectrum of Alzheimer's disease (AD)?

Findings: In a longitudinal study of 790 patients with mild cognitive impairment (MCI) and AD dementia, serial measurements of plasma p-tau181 and NfL were collected annually over four years. P-tau181 and NfL levels were elevated in those with apathy or anxiety compared to those without. The rate of NfL increase, an indicator of neurodegeneration, was significantly higher in those with apathy.

Meaning: The presence of anxiety and apathy was associated with elevated biomarkers of neurodegeneration in MCI and AD dementia. Notably, apathy was linked to a faster rate of NfL increase, suggesting an accelerated neurodegenerative process.

141

142 Abstract

143 Importance: While apathy and affective neuropsychiatric symptoms (NPS) are common in the
144 clinical spectrum of Alzheimer's disease (AD), their neurobiological correlates remain unclear.

Objective: To longitudinally examine plasma markers of neurodegeneration (neurofilament light
chain; NfL) and tau pathology (phosphorylated at threonine 181; p-tau181) and their associations
with apathy and affective symptoms in individuals with clinical diagnoses of AD dementia and
mild cognitive impairment (MCI).

Design, Setting, Participants and Exposure: This cohort study used longitudinal data from the Alzheimer Disease Neuroimaging Initiative (ADNI). Individuals with clinical diagnoses of MCI and AD dementia were enrolled in ADNI with serial annual blood samples over a four-year period, which were analyzed for NfL and p-tau181 using ultrasensitive techniques. Study data were accessed between July and September 2024.

Main Outcomes and Measures: The presence of neuropsychiatric symptoms was determined using the Neuropsychiatric Interview (NPI). We analyzed the trajectory of plasma NfL and ptau181 in each NPS using general linear mixed-effects models adjusted for age and sex.

157 **Results:** There were 790 participants with AD dementia and MCI (mean [SD] age 72.7 [7.6] 158 years; 333 females, 42%) and 417 healthy controls. The most common NPS was depression (n =159 428; 54%), followed by irritability (n = 419; 53%), apathy (n = 348; 44%) and anxiety (n = 341; 160 43%). In the AD dementia and MCI group, apathy and anxiety were associated with higher 161 levels of both NfL and p-tau181 after controlling for cognitive and functional decline. Moreover, 162 apathy was associated with higher rate of NfL increase longitudinally. Depression at baseline 163 was initially associated with higher NfL and p-tau181 levels, but this did not remain significant 164 in the sensitivity analyses.

165 **Conclusion and Relevance:** This study found that in individuals with clinical AD, apathy and 166 anxiety are associated greater tau and neurodegenerative burden. Furthermore, those with apathy 167 had a higher rate of NfL increase, which suggests an accelerated neurodegenerative process. 168 These findings highlight that these symptoms be indicative of AD pathology severity and have 169 implications for potential treatments which target tau pathology.

170

171 Keywords: Neuropsychiatric symptoms, Blood-based biomarkers, Alzheimer's disease,
172 Depression, Apathy, Anxiety, Phosphorylated tau 181, Neurofilament light chain,

173 Background

Neuropsychiatric symptoms (NPS) are prevalent in individuals across the clinical spectrum of Alzheimer's disease (AD) including mild cognitive impairment (MCI) and AD dementia.^{1,2} These symptoms often co-occur in clusters, with affective symptoms (depression and anxiety) and apathy among the most prevalent.^{1–4} NPS have been associated with worse cognitive decline, higher mortality rates, and greater caregiver burden.^{5–7} Despite their prevalence and impact, the neurobiological mechanisms underlying NPS, and their contribution to disease progression remain inadequately understood.

Previous literature have reported mixed findings regarding the association between AD biomarkers and NPS.^{8,9} Several factors may account for the inconsistent results. Many studies may be underpowered to detect the subtle associations between NPS and biomarkers.¹⁰ Additionally, some studies have grouped NPS together,^{2,6} such as within the mild behavioral impairment (MBI) framework,^{11,12} potentially obscuring the effects of individual symptom groups.

Ultrasensitive blood-based immunoassays can now detect and track the progression of ADrelated neuropathological processes. Plasma tau phosphorylated at threonine 181 (p-tau181) shows strong associations with tau pathology and amyloid deposition.¹³ Neurofilament light chain protein (NfL) reflects neuroaxonal damage,^{14,15} including in AD dementia.^{16,17} These blood-based biomarkers offer minimally invasive alternatives to traditional cerebrospinal fluid (CSF) and imaging biomarkers.^{18,19}

A recent study found that that the emergence of psychosis was associated with elevated plasma levels of p-tau181 and NfL in individuals across the clinical spectrum of AD.²⁰ However, no studies have explored their relationship to other NPS longitudinally, such as apathy and affective symptoms, which are the most common neuropsychiatric manifestations of AD dementia and MCI.

Our primary aim was to explore the association between apathy and affective NPS (depression, anxiety) with blood NfL and p-tau181 longitudinally in individuals with clinical diagnoses of AD dementia and MCI. As a secondary aim, we explored plasma biomarker associations with

- 201 other NPS, including delusions, hallucinations, agitation, irritability, disinhibition, elation,
- 202 appetite disturbance, sleep disturbance and aberrant motor symptoms.

203 Methods

204 This longitudinal study used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) 205 database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, 206 led by Principal Investigator Michael W. Weiner, MD. The ADNI participants have been 207 recruited from more than 50 sites across the United States and Canada. We downloaded the data from the ADNI database on the 22nd July 2024. Regional ethical committees of all institutions 208 209 approved the ADNI study. All study participants gave written informed consent. This study was 210 carried out according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.²¹ 211

212 Participants

This cohort has been described in a previous publication.¹⁹ In brief, the cohort consisted of 213 214 patients with clinical diagnoses of AD dementia and MCI, and an additional group of cognitively 215 unimpaired (CU) participants with available plasma NfL and p-tau181 measurements collected 216 annually over four years. All ADNI participants had no significant neurological disease other 217 than AD. The following measures were also obtained during the annual visits: Mini-Mental State 218 Examination (MMSE), Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), hippocampal volume acquired using 3-T MRI scanners.²² and Florbetapir positron emission tomography 219 220 standardized uptake value ratio (AV45 PET SUVR) which quantifies amyloid plaque burden.²³ 221 The CU participants reported a MMSE score of 24 or higher and a CDR score of zero. The MCI 222 participants reported an MMSE score of 24 or higher and a CDR score of 0.5. The patients with AD dementia fulfilled the clinical diagnostic criteria for probable AD,²⁴ reported an MMSE 223 224 score between 20 and 26, and a CDR score from 0.5 to 1.0.

The presence of NPS was assessed with the Neuropsychiatric Inventory (NPI), an informantbased scale that examines 12 neuropsychiatric domains through a structured interview with the caregiver. The NPS in the NPI are apathy, anxiety, depression, irritability, elation, disinhibition, aggression, delusions, hallucinations, aberrant motor symptoms, appetite disturbance and sleep disturbance.

For each NPS of interest (i.e. apathy), participants with AD dementia and MCI were distributed in 3 groups according to presence or absence of the NPS longitudinally: (1) participants without

- the specific NPS over the course of the study (i.e., apathy absent), (2) participants with the
- specific NPS at baseline (i.e., apathy baseline), and (3) participants with the specific NPS at any
- time point over the course of the study (i.e., apathy incident), consistent with a previous study by
- 235 Gomar et al. exploring psychosis in the ADNI cohort.²⁰

236 Samples Analyses

Plasma p-tau181 and NfL concentrations were measured using Single molecule array (Simoa)
technology (Quanterix, Billerica, MA) at the Clinical Neurochemistry Laboratory, University of
Gothenburg, Mölndal, Sweden, as previously described.^{19,20}

240 Statistical Analyses

All statistical analyses were performed using R version 4.2.2 (2022-10-31), the lmer package, Jamovi version 2.6.0 and GAMLj package.^{25–28} For the participant characteristics, demographic and clinical status between groups at baseline were compared using general linear models (GLMs) for continuous variables, and χ^2 test of independence were used for comparisons in categorical variables.

246 To explore whether a specific NPS (i.e. apathy) was associated with NfL or p-tau181 levels over 247 time, a general linear mixed-effects model (GLMM) was estimated to analyze the longitudinal 248 biomarkers (NfL and p-tau181) trajectories in each NPS subgroups (i.e. apathy absent, apathy 249 baseline and apathy incident) with random intercepts and slopes for each participant. For the 250 primary analysis, age and sex were included as covariates, using residual (restricted) maximum 251 likelihood estimation and assuming an unstructured covariance matrix. Plasma NfL and p-tau181 252 levels were log-transformed. All continuous variables were centered and scaled prior to analysis. 253 The rate of change of biomarkers within groups (β slopes) was computed as averaged individual 254 slopes from GLMMs that included random intercepts and slopes. Robust standard errors and 255 confidence intervals were computed using bootstrapping with 2000 replicates. We performed 256 simple effects analysis to determine whether the presence of a specific NPS (i.e. apathy baseline 257 vs apathy absent, apathy incident vs apathy absent) was associated with significantly higher NfL 258 levels or slope compared to those without the specific NPS (i.e. absent baseline). All p values 259 were 2-sided and corrected for multiple testing using the Benjamin-Hochberg adjusted false 260 discovery rate (FDR) of 5%.

- 261 We performed additional **sensitivity analyses** to ensure the findings in the primary outcomes of
- 262 interest (apathy, anxiety and depression) were robust. We added CDR-SB and MMSE scores as
- covariates to account for any confounding effects of dementia severity. We also repeated the
- 264 GLMMs for the subgroup of individuals who demonstrated amyloid positivity during the study
- 265 (AV45 SUVR > 1.11). As a post-hoc analysis, we also performed GLMMs using the severity
- score for each NPS derived from the NPI (frequency x severity) adjusting for age and sex as
- 267 covariates.

268 **Results**

269 A total of 1207 participants from ADNI had their serial plasma samples analyzed for p-tau181 270 and NfL are summarized in Table 1. For the cohort across the clinical AD spectrum (AD 271 dementia and MCI; n = 790), the mean age was 72.7 (SD 7.63) years, with 333 females (42%). 272 The mean CDR-SB was 5.3 for AD dementia and 1.5 for MCI, which is the equivalent of mild 273 and very mild severity respectively. 161 (88%) individuals diagnosed with AD dementia and 327 274 (62%) individuals with MCI were amyloid-positive respectively. The most common NPS was 275 depression (54%), followed by irritability (53%), apathy (44%) and anxiety (43%). The 276 prevalence of the secondary NPS of interest are listed in sTable 1.

277 Associations between NPS and plasma NfL over time in the Clinical AD Spectrum

The overall associations between NPS and plasma NfL are shown in Figure 1. The primary NPS of interest are summarized in Figure 1 and Table 2.

280 <u>Apathy</u>

The GLMM revealed that the **apathy baseline group** had **higher NfL levels** over time, compared to the apathy absent group ($\beta = 0.18$, p < 0.001). This finding remained robust in sensitivity analyses adjusting for CDR-SB and MMSE. The **apathy incident group** had significantly higher NfL levels compared to the **apathy absent group** ($\beta = 0.10$, p = 0.029). This finding did not survive the sensitivity analyses. The simple effects analysis showed that both apathy baseline ($\beta = 0.16$, p < 0.001) and apathy incident ($\beta = 0.09$, p = 0.016 groups had higher NfL levels than the apathy absent group at the baseline timepoint.

In terms of the **rate of NfL increase, apathy baseline group** ($\beta = 0.04$, p < 0.001) **and apathy incident group** ($\beta = 0.03$, p = 0.009) exhibited higher rates of NfL increase compared to the **apathy absent group**. The significant finding for the apathy baseline group was robust in the sensitivity analyses.

292 <u>Anxiety</u>

293 The GLMM exploring the impact of anxiety on NfL levels showed that **anxiety absent group** 294 had significantly higher NfL levels compared to the **anxiety absent group** ($\beta = 0.16$, p < 0.001).

The **anxiety incident group** had significantly higher NfL levels than the **anxiety absent group** ($\beta = 0.16$, p < 0.001). Both findings were robust in the sensitivity analyses adjusting for CDR-SB and MMSE, and the subgroup analyses of amyloid positive individuals. The simple effects analysis also showed that both anxiety baseline ($\beta = 0.16$, p < 0.001) and anxiety incident ($\beta =$ 0.14, p < 0.001) groups had higher NfL levels than the anxiety absent group at the baseline timepoint.

Neither anxiety baseline group nor anxiety incident group had significantly different rate of NfLincrease compared to the anxiety absent group.

303 Depression

The GLMM examining depression found that the **depression baseline group** exhibited significantly higher NfL levels than the **depression absent group** ($\beta = 0.11$, p = 0.009). This finding was significant in the subgroup analysis of individuals who were amyloid positive, however this did not survive the sensitivity analyses adjusting for MMSE and CDR-SB. At the baseline timepoint, the depression baseline group had higher NfL levels than the depression absent group ($\beta = 0.13$; p < 0.001) whilst there were no significant differences between the depression incident and depression absent groups ($\beta = 0.06$, p = 0.104).

311 The depression baseline group had a significantly higher rate of NfL increase compared to 312 the depression absent group ($\beta = 0.02$, p = 0.048). However, this did not survive the sensitivity 313 analyses adjusting for CDR-SB and MMSE.

314 Other NPS of interest

For our secondary aims, the GLMMs found that baseline symptoms of delusions, appetite disturbances, agitation, disinhibition, and motor symptoms were associated with elevated NfL levels compared to those who did not develop the NPS over time. Individuals who developed (NPS incident) appetite disturbances, delusions, hallucinations, and motor symptoms were associated with increased NfL levels compared to their respective absent groups. Disinhibition baseline and elation incident showed significantly steeper increases in NfL levels compared to the absent groups.

322 Associations between each NPS severity score and NfL over time

For post-hoc analysis where each NPS was added to the GLMM as a severity variable, apathy and depression were associated with higher NfL levels, and the interaction terms for rate of increase were also significantly high. The post-hoc analyses are summarized in sTable 3.

326

327 Associations between NPS and plasma p-tau181 over time in the Clinical AD Spectrum

The overall associations between NPS and plasma p-tau181 are shown in Figure 1. The primary NPS of interest are summarized in Figure 1 and Table 2. None of the NPS groups had significantly higher rates of p-tau181 change.

331 Apathy

332 GLMM showed that the apathy baseline group had higher p-tau181 levels compared to the 333 apathy absent group ($\beta = 0.15$, p = 0.015). This finding was still significant in the subgroup 334 analysis for amyloid positive individuals, but not in the sensitivity analyses controlling for CDR-335 SB. The apathy incident group also had higher p-tau181 levels compared to the apathy absent 336 group ($\beta = 0.14$, p = 0.015). This finding survived sensitivity analyses controlling for CDR-SB 337 and MMSE. At the baseline timepoint, both the apathy baseline ($\beta = 0.24$, p < 0.001) and apathy 338 incident ($\beta = 0.21$, p < 0.001) groups had significantly higher levels compared to apathy absent 339 group.

340 Depression

GLMM showed that the depression baseline group had higher p-tau181 levels compared to the depression absent group ($\beta = 0.11$, p = 0.048). This finding was still significant in the subgroup analysis of amyloid positive individuals but did not survive the sensitivity analyses adjusting for CDR-SB and MMSE. At the baseline timepoint, the depression baseline group had significantly higher levels compared to the depression absent group ($\beta = 0.17$, p < 0.001).

346 Anxiety

GLMM showed that the anxiety baseline group had higher p-tau181 levels compared to the anxiety absent group ($\beta = 0.19$, p = 0.001). This finding was robust in the sensitivity analyses controlling for CDR-SB and MMSE. At the baseline timepoint, both the anxiety baseline ($\beta =$

0.25, p < 0.001) and anxiety incident ($\beta = 0.17$, p = 0.001) groups had significantly higher levels compared to anxiety absent group.

352 Other NPS of interest

The secondary NPS of interest are summarized in sTable 2. Delusions, agitation, and motor symptoms at baseline were associated with higher p-tau181 levels compared to individuals without these symptoms. Furthermore, delusion incident and motor symptom incident also had higher p-tau181 levels compared to individuals without those symptoms.

357 Associations between each NPS severity score and NfL over time

358 When each NPS was added to the GLMM as a severity variable, depression severity was

associated with p-tau181 levels (p = 0.009), whilst apathy severity was trending (p = 0.053).

360

361 **Discussion**

362 In this longitudinal study, we found that plasma p-tau181 and NfL were significantly elevated in 363 participants with apathy and anxiety at baseline or follow-up, compared to those without these 364 symptoms. Moreover, participants with apathy showed a faster rate of NfL increase over time, 365 suggesting accelerated neurodegeneration. Although depression showed an association with NfL 366 and p-tau181, this did not remain significant in the sensitivity analyses controlling for cognitive 367 and functional decline. These results underscore the potential relationship between 368 neuropsychiatric symptoms and neurodegenerative biomarkers, particularly NfL, in the AD 369 continuum.

370 Our findings support previous literature linking apathy with tau pathology and neurodegeneration.²⁹⁻³² In particular, Kitamura et al. conducted one of the few multi-modal 371 studies which investigated apathy in AD patients (n=17) with structural and tau imaging.³³ They 372 373 found an association between apathy, elevated tau deposition and decreased cortical thickness 374 the in orbitofrontal cortex (OFC). The authors hypothesized that increased tau accumulation 375 leads to degeneration of OFC thickness and integrity, thereby disrupting the limbic system, and contributing to apathy.^{34,35} Our observation that participants developing apathy also exhibited 376 377 higher levels NfL and p-tau181 may be reflective of the preclinical manifestation of tau 378 accumulation and neurodegeneration before the onset of clinical apathy. A longitudinal, multi-379 modal approach incorporating fluid-based AD biomarkers and neuroimaging is needed to further 380 validate these findings.

Notably, some studies did not find an association between tau pathology and apathy.^{29,36–39} This discrepancy may be due to these studies being underpowered or cross-sectional,^{37,40} limiting their ability to detect subtle differences in tau pathology. Our study demonstrates the advantage of using blood-based AD biomarkers, which are more accessible and allow for larger, longitudinal data sets.^{10,41} However, a key limitation of blood biomarkers is that they provide a measure of overall pathology, without offering insights into specific brain regions or circuits directly involved.

The higher rate of NfL increase over time suggests heightened neurodegeneration in AD dementia and MCI patients with apathy, independent of cognitive and functional decline. Apathy has been linked to more rapid disease progression in AD, with several studies identifying it as a predictor of faster cognitive decline⁴² and earlier mortality.⁴³ This may be due to the presence of apathy resulting in less optimal dementia care given its impact on functioning and caregiver burden, leading to worse outcomes.⁴² These findings reinforce the importance of identifying and treating neuropsychiatric symptoms including apathy in AD patients.⁴⁴ Furthermore, plasma NfL may be a candidate for apathy-specific biomarker in AD to guide treatment.⁴⁵

Anxiety was significantly associated with both NfL and p-tau181 in our study, aligning with previous reports linking anxiety to AD and neurodegenerative markers.^{36,39} Our longitudinal study builds on recent literature in CSF and cross-sectional data, including Banning et al's investigation which found an association between anxiety and CSF p-tau181.²⁹ Anxiety has been conceptualized as an early manifestation of compensatory behavior in response to preclinical cognitive decline,^{29,46} suggesting that its presence may serve as a behavioral signal of p-tau181 accumulation and subsequent neurodegeneration.

Although depression has been linked to AD progression,^{47–49} our study did not find a significant 403 404 association between depression and NfL or p-tau181 after controlling for AD severity, consistent with other research.^{29,36,50} One hypothesis is that previous studies may have conflated measures 405 406 of depression with other NPS, given the significant overlap between depression with apathy and 407 anxiety. For example, Krell-Roesch et al. observed a relationship between clinical depression as 408 defined by Beck Depression Inventory II (BDI-II) score and AD biomarkers, but not when depression was based on informant-observed NPI-Q.⁹ As several of the 21 items in BDI-II may 409 410 be influenced by apathy, including loss of interest, energy and pleasure, the presence of apathy 411 may have increased their BDI-II total score to meeting the cut-off score for depression. This 412 highlights the heterogeneous nature of depression, and its apparent association with AD 413 biomarkers may depend on the instrument that is used to define depression. However, our 414 interpretation in this context is limited to depression symptoms, as our study could not control 415 for a history of depression due to the lack of available data. Future studies that better characterize 416 depression history in participants are needed.

417 As for our secondary aims, our study replicated findings that delusions and hallucinations are 418 associated with higher NfL and p-tau181 levels.^{20,51} Our results also align with existing literature 419 showing that agitation⁵⁰ and motor symptoms⁵¹ are associated with disease progression.

20

There are several limitations of this study. The number of participants with available biomarker samples decreased during follow-up. As ADNI excluded participants with a history of major depression or bipolar disorder within the past year, it limits the generalizability of our findings to individuals with more severe psychiatric comorbidities, which is important given that mood disorders may have a mild influence on plasma NfL.⁵³ Our study focused on p-tau181, but other tau species like p-tau217 may offer additional insights into tau pathology in AD. Future studies should explore the role of different tau species in relation to neuropsychiatric symptoms.

In conclusion, our findings emphasize the complex relationship between NPS and AD biomarkers, particularly NfL, and suggest that apathy may be linked to accelerated neurodegeneration. The observed changes in AD biomarkers across various NPS profiles provide valuable insights into the neurobiological mechanisms underlying these symptoms. Further research is required to better understand the role of these symptoms in disease progression and to

432 develop targeted interventions aimed at slowing cognitive and functional decline in AD.

433 References

- Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in
 Alzheimer's disease: Systematic review and meta-analysis. *J Affect Disord*. 2016;190:264 271. doi:10.1016/j.jad.2015.09.069
- 437 2. Eikelboom WS, van den Berg E, Singleton EH, et al. Neuropsychiatric and Cognitive
 438 Symptoms Across the Alzheimer Disease Clinical Spectrum. *Neurology*. 2021;97(13):e1276439 e1287. doi:10.1212/WNL.00000000012598
- Arenare G, Manca R, Caffarra P, Venneri A. Associations between Neuropsychiatric
 Symptoms and Alzheimer's Disease Biomarkers in People with Mild Cognitive Impairment. *Brain Sci.* 2023;13(8):1195. doi:10.3390/brainsci13081195
- 443 4. Greig Custo MT, Lang MK, Barker WW, et al. The association of depression and apathy
 444 with Alzheimer's disease biomarkers in a cross-cultural sample. *Appl Neuropsychol Adult*.
 445 2024;31(5):849-865. doi:10.1080/23279095.2022.2079414
- Jin P, Xu J, Liao Z, et al. A review of current evidence for mild behavioral impairment as an
 early potential novel marker of Alzheimer's disease. *Front Psychiatry*. 2023;14:1099333.
 doi:10.3389/fpsyt.2023.1099333
- 6. Ghahremani M, Wang M, Chen HY, Zetterberg H, Smith E, Ismail Z. Plasma
 Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and
 Prodromal Alzheimer Disease. *Neurology*. 2023;100(7):e683-e693.
 doi:10.1212/WNL.00000000201517
- 453
 7. Dolphin H, Dyer AH, McHale C, O'Dowd S, Kennelly SP. An Update on Apathy in
 454 Alzheimer's Disease. *Geriatrics (Basel)*. 2023;8(4):75. doi:10.3390/geriatrics8040075
- 8. Ng KP, Chiew H, Rosa-Neto P, Kandiah N, Ismail Z, Gauthier S. Associations of AT(N)
 biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and
 cognitively unimpaired individuals. *Translational Neurodegeneration*. 2021;10(1):11.
 doi:10.1186/s40035-021-00236-3
- 459
 9. Krell-Roesch J, Rakusa M, Syrjanen JA, et al. Association between CSF biomarkers of
 460 Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging.
 461 Alzheimer's & Dementia. 2023;19(10):4498-4506. doi:10.1002/alz.12557
- 462 10. Arslan B, Zetterberg H. Neurofilament light chain as neuronal injury marker what is
 463 needed to facilitate implementation in clinical laboratory practice? *Clinical Chemistry and*464 *Laboratory Medicine (CCLM)*. 2023;61(7):1140-1149. doi:10.1515/cclm-2023-0036
- 11. Naude JP, Gill S, Hu S, et al. Plasma neurofilament light: A marker of neurodegeneration in mild behavioral impairment. Alzheimer's Disease Neuroimaging Initiative, ed. *Journal of Alzheimer's Disease*. 2020;76(3):1017-1027. doi:10.3233/JAD-200011

- 468 12. Lussier FZ, Pascoal TA, Chamoun M, et al. Mild behavioral impairment is associated with
 469 β□amyloid but not tau or neurodegeneration in cognitively intact elderly individuals.
 470 *Alzheimers Dement.* 2020;16(1):192-199. doi:10.1002/alz.12007
- 471 13. Karikari TK, Ashton NJ, Brinkmalm G, et al. Blood phospho-tau in Alzheimer disease:
 472 analysis, interpretation, and clinical utility. *Nat Rev Neurol*. 2022;18(7):400-418.
 473 doi:10.1038/s41582-022-00665-2
- 474 14. Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H. Cerebrospinal fluid tau,
 475 neurogranin, and neurofilament light in Alzheimer's disease. *EMBO molecular medicine*.
 476 2016;8(10):1-13.
- 477 15. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological
 478 disorders. *Nature Reviews Neurology*. 2018;14(10):577-589. doi:10.1038/s41582-018-0058479 z
- 480
 481
 481
 482
 482
 483
 484
 484
 485
 485
 486
 486
 486
 487
 486
 486
 487
 486
 486
 487
 488
 488
 488
 480
 480
 480
 480
 481
 481
 482
 482
 482
 483
 484
 484
 484
 485
 486
 486
 487
 487
 488
 488
 488
 488
 480
 480
 480
 480
 481
 481
 482
 482
 482
 482
 482
 483
 484
 484
 484
 484
 484
 485
 484
 485
 485
 486
 486
 487
 487
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
 488
- 483
 17. Eratne D, Loi SM, Li QX, et al. Cerebrospinal fluid neurofilament light chain differentiates
 484 primary psychiatric disorders from rapidly progressive, Alzheimer's disease and
 485 frontotemporal disorders in clinical settings. *Alzheimer's & Dementia*. 2022;18(11):2218486 2233. doi:10.1002/alz.12549
- 487 18. Mattsson-Carlgren N, Salvadó G, Ashton NJ, et al. Prediction of Longitudinal Cognitive
 488 Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. *JAMA Neurol.*489 2023;80(4):360. doi:10.1001/jamaneurol.2022.5272
- 490 19. Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between
 491 Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With
 492 Alzheimer Disease. *JAMA Neurol*. 2019;76(7):791-799. doi:10.1001/jamaneurol.2019.0765
- 493 20. Gomar JJ, Koppel J. Psychosis in Alzheimer Disease and Elevations in Disease-Relevant
 494 Biomarkers. *JAMA Psychiatry*. Published online June 26, 2024.
 495 doi:10.1001/jamapsychiatry.2024.1389
- 496 21. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational
 497 Studies in Epidemiology (STROBE) statement: guidelines for reporting observational
 498 studies. *Ann Intern Med.* 2007;147(8):573-577. doi:10.7326/0003-4819-147-8-200710160499 00010
- Jack Jr. CR, Bernstein MA, Fox NC, et al. The Alzheimer's disease neuroimaging initiative
 (ADNI): MRI methods. *Journal of Magnetic Resonance Imaging*. 2008;27(4):685-691.
 doi:10.1002/jmri.21049

- 503 23. Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and
 504 cerebrospinal fluid measurements of β-amyloid. *Ann Neurol*. 2013;74(6):826-836.
 505 doi:10.1002/ana.23908
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis
 of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of
 Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*.
 1984;34(7):939-944. doi:10.1212/wnl.34.7.939
- 510 25. Gallucci M. GAMLj: General analyses for linear models. Published online 2019.
 511 https://gamlj.github.io
- 512 26. jamovi (Version 1.6). Published online 2021. https://www.jamovi.org
- 513 27. Kuznetsova A, Brockhoff PB, Christensen RHB. ImerTest Package: Tests in Linear Mixed
 514 Effects Models. *J Stat Soft*. 2017;82(13). doi:10.18637/jss.v082.i13

515 28. R Core Team. R: A language and environment for statistical computing. Published online
 516 2021. https://www.R-project.org/

517 29. Banning LCP, Ramakers IHGB, Köhler S, et al. The Association Between Biomarkers and
518 Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum. *The American*519 *Journal of Geriatric Psychiatry*. 2020;28(7):735-744. doi:10.1016/j.jagp.2020.01.012

- 30. Skogseth R, Mulugeta E, Ballard C, et al. Neuropsychiatric Correlates of Cerebrospinal Fluid
 Biomarkers in Alzheimer's Disease. *Dementia and Geriatric Cognitive Disorders*.
 2008;25(6):559-563. doi:10.1159/000137671
- 31. Pichet Binette A, Vachon-Presseau É, Morris J, et al. Amyloid and Tau Pathology
 Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle
 in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. *Biol Psychiatry*. 2021;89(8):776-785. doi:10.1016/j.biopsych.2020.01.023
- 527 32. Donovan NJ, Hsu DC, Dagley AS, et al. Depressive symptoms and biomarkers of
 528 Alzheimer's disease in cognitively normal older adults. *J Alzheimers Dis.* 2015;46(1):63-73.
 529 doi:10.3233/JAD-142940
- 530 33. Kitamura S, Shimada H, Niwa F, et al. Tau-induced focal neurotoxicity and network
 531 disruption related to apathy in Alzheimer's disease. *J Neurol Neurosurg Psychiatry*.
 532 2018;89(11):1208-1214. doi:10.1136/jnnp-2018-317970
- 34. Steffens DC, Fahed M, Manning KJ, Wang L. The neurobiology of apathy in depression and neurocognitive impairment in older adults: a review of epidemiological, clinical, neuropsychological and biological research. *Transl Psychiatry*. 2022;12(1):1-16.
 doi:10.1038/s41398-022-02292-3
- 537 35. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia
 538 circuits. *Cereb Cortex*. 2006;16(7):916-928. doi:10.1093/cercor/bhj043

- 36. Banning LCP, Ramakers IHGB, Deckers K, Verhey FRJ, Aalten P. Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer's disease: A systematic literature review. *Neuroscience & Biobehavioral Reviews*. 2019;107:346-359.
 doi:10.1016/j.neubiorev.2019.09.014
- 543 37. Donovan NJ, Wadsworth LP, Lorius N, et al. Regional cortical thinning predicts worsening
 apathy and hallucinations across the Alzheimer's disease spectrum. *Am J Geriatr Psychiatry*.
 2014;22(11):1168-1179. doi:10.1016/j.jagp.2013.03.006
- 38. Peters ME, Schwartz S, Han D, et al. Neuropsychiatric symptoms as predictors of
 progression to severe Alzheimer's dementia and death: The Cache County Dementia
 Progression Study. *Am J Psychiatry*. 2015;172(5):460-465.
 doi:10.1176/appi.ajp.2014.14040480
- 39. Ramakers IHGB, Verhey FRJ, Scheltens P, et al. Anxiety is related to Alzheimer
 cerebrospinal fluid markers in subjects with mild cognitive impairment. *Psychological Medicine*. 2013;43(5):911-920. doi:10.1017/S0033291712001870
- 40. Ozaki T, Hashimoto N, Udo N, Narita H, Nakagawa S, Kusumi I. Neurobiological
 correlation between phosphorylated tau and mood symptoms in memory clinic patients. *Psychogeriatrics*. 2023;23(6):954-962. doi:10.1111/psyg.13016
- 41. Chatterjee P, Pedrini S, Ashton NJ, et al. Diagnostic and prognostic plasma biomarkers for
 preclinical Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2022;18(6):1141-1154. doi:10.1002/alz.12447
- Liew TM. Neuropsychiatric symptoms in early stage of Alzheimer's and non-Alzheimer's dementia, and the risk of progression to severe dementia. *Age Ageing*. 2021;50(5):1709-1718. doi:10.1093/ageing/afab044
- 43. Vilalta-Franch J, Calvó-Perxas L, Garre-Olmo J, Turró-Garriga O, López-Pousa S. Apathy
 syndrome in Alzheimer's disease epidemiology: prevalence, incidence, persistence, and risk
 and mortality factors. *J Alzheimers Dis.* 2013;33(2):535-543. doi:10.3233/JAD-2012-120913
- 44. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024
 report of the Lancet standing Commission. *The Lancet*. 2024;404(10452):572-628.
 doi:10.1016/S0140-6736(24)01296-0
- 45. Mortby ME, Adler L, Agüera-Ortiz L, et al. Apathy as a Treatment Target in Alzheimer's
 Disease: Implications for Clinical Trials. *The American Journal of Geriatric Psychiatry*.
 2022;30(2):119-147. doi:10.1016/j.jagp.2021.06.016
- 46. Hanseeuw BJ, Jonas V, Jackson J, et al. Association of anxiety with subcortical amyloidosis
 in cognitively normal older adults. *Mol Psychiatry*. 2020;25(10):2599-2607.
 doi:10.1038/s41380-018-0214-2

- 47. Lanctôt KL, Amatniek J, Ancoli-Israel S, et al. Neuropsychiatric signs and symptoms of
 Alzheimer's disease: New treatment paradigms. *Alzheimers Dement (N Y)*. 2017;3(3):440449. doi:10.1016/j.trci.2017.07.001
- 48. Lee GJ, Lu PH, Hua X, et al. Depressive symptoms in mild cognitive impairment predict
 greater atrophy in Alzheimer's disease-related regions. *Biol Psychiatry*. 2012;71(9):814-821.
 doi:10.1016/j.biopsych.2011.12.024
- 49. Gatchel JR, Donovan NJ, Locascio JJ, et al. Depressive Symptoms and Tau Accumulation in
 the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A
 Pilot Study. *J Alzheimers Dis.* 2017;59(3):975-985. doi:10.3233/jad-170001
- 50. Showraki A, Murari G, Ismail Z, et al. Cerebrospinal Fluid Correlates of Neuropsychiatric
 Symptoms in Patients with Alzheimer's Disease/Mild Cognitive Impairment: A Systematic
 Review. J Alzheimers Dis. 2019;71(2):477-501. doi:10.3233/JAD-190365
- 586 51. Huang L, Xie F, Guo Q. Neuropsychiatric symptoms in Alzheimer's continuum and their
 587 association with plasma biomarkers. *Journal of Affective Disorders*. 2024;348:200-206.
 588 doi:10.1016/j.jad.2023.12.062
- 52. Rabl M, Zullo L, Lewczuk P, et al. Plasma neurofilament light, glial fibrillary acid protein,
 and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related
 clinical disease progression. *Alzheimer's Research & Therapy*. 2024;16(1):165.
 doi:10.1186/s13195-024-01526-4
- 53. Kang MJ, Grewal J, Eratne D, et al. Neurofilament light and glial fibrillary acidic protein in
 mood and anxiety disorders: A systematic review and meta-analysis. Published online March
 9, 2024. doi:10.1101/2024.03.07.24303938

596

597

Characteristic	$\frac{\mathbf{CU}}{\mathbf{N}=417^1}$	AD Dementia $N = 220^1$	$\frac{\mathbf{MCI}}{\mathbf{N} = 570^{1}}$	p- value ²	Group Comparison
Age	73.5 [5.9]	74.2 [7.7]	72.0 [7.5]	< 0.001	$CU > MCI^{**}$ AD Dementia > MCI^{**}
Sex: Female	222 (53%)	90 (41%)	244 (43%)	< 0.001	CU > MCI ^{**} CU > AD Dementia ^{**}
Education (years)	16.5 [2.6]	15.8 [2.8]	16.0 [2.8]	0.005	$CU > MCI^{**}$ $CU > AD Dementia^{**}$
APOE e4 1	105 / 417 (25%)	105 (48%)	210 / 570 (37%)	< 0.001	CU < MCI ^{**}
2	8 / 417 (1.9%)	43 (20%)	49 / 570 (8.6%)		CU < AD Dementia ^{**} MCI < AD Dementia ^{**}
Plasma NfL (pg/mL)	38.3 [23.2]	51.1 [22.6]	40.5 [23.4]	<0.001	CU < AD Dementia ^{**} CU < MCI [*] MCI < AD Dementia ^{**}
Plasma p-tau181 (pg/mL)	N = 416 17.1 [25.2]	23.7 [8.9]	18.5 [11.9]	<0.001	CU < AD Dementia ^{**} CU < MCI ^{**} MCI < AD Dementia ^{**}
MMSE	29.1 [1.2]	22.1 [3.5]	N = 569 28.1 [1.7]	<0.001	CU > MCI ^{**} CU > AD Dementia ^{**} MCI > AD Dementia ^{**}
CDR-SB	N = 416 0.1 [0.3]	N = 219 5.3 [2.5]	N = 569 1.5 [1.0]	<0.001	CU > MCI ^{**} CU > AD Dementia ^{**} MCI > AD Dementia ^{**}
NPI Score	0.9 [2.4]	6.6 [8.9]	2.9 [5.7]	<0.001	CU < AD Dementia ^{**} CU < MCI ^{**} MCI < AD Dementia ^{**}
Hippocampus	N = 360	N = 163	N = 483	< 0.001	$CU > MCI^{**}$
volume at baseline (mm ³)	7388 [930]	5757 [1058]	7024 [1087]		CU > AD Dementia ^{**} MCI > AD Dementia ^{**}
Florbetapir	N = 357	N = 175	N = 499	< 0.001	CU < MCI ^{**}
(AV45) PET SUVR	1.1 [0.2]	1.4 [0.2]	1.2 [0.2]		CU < AD Dementia ^{**} MCI < AD Dementia ^{**}
Depression	N = 415	N = 220	N = 570	< 0.001	CU < MCI ^{**}
Absent	313 (75%)	96 (44%)	266 (47%)		CU < AD Dementia MCI < AD Dementia ^{**}
Baseline	38 (9.2%)	93 (42%)	155 (27%)		
Incident	64 (15%)	31 (14%)	149 (26%)		
Anxiety	N = 415	N = 220	N = 570	< 0.001	CU < MCI ^{**}
Absent	366 (88%)	104 (47%)	345 (61%)		CU < AD Dementia ^{**} MCI < AD Dementia ^{**}
Baseline	23 (5.5%)	73 (33%)	95 (17%)		
Incident	26 (6.3%)	43 (20%)	130 (23%)		

598 Table 1 – Participant Characteristics at Baseline

Characteristic	$\begin{array}{c} \mathbf{CU} \\ \mathbf{N} = 417^1 \end{array}$	AD Dementia $N = 220^1$	$\frac{\mathbf{MCI}}{\mathbf{N} = 570^{1}}$	p- value ²	Group Comparison
Apathy	N = 415	N = 220	N = 570	<0.001	CU < MCI ^{**}
Absent	378 (91%)	90 (41%)	352 (62%)		CU < AD Dementia MCI < AD Dementia ^{**}
Baseline	11 (2.7%)	93 (42%)	95 (17%)		
Incident	26 (6.3%)	37 (17%)	123 (22%)		

¹Mean [SD]; n / N (%)

²Kruskal-Wallis rank sum test; Pearson's Chi-squared test

*p < 0.05

***p < 0.001

AD = Alzheimer's disease; APOE = Apolipoprotein E; CDR-SB = Clinical Dementia Rating Sum of

Boxes; CN = cognitively unimpaired; MCI = mild cognitive impairment; MMSE, Mini-Mental State

Examination; NfL = neurofilament light chain; p-tau181 = phosphorylated tau at threonine 181;

Florbetapir (AV45) PET SUVR = positron emission tomography standardized uptake value ratio;

603

NPS	Mean or Slope	Comparison Groups	Plasma NfL	Plasma p-tau181
Apathy	Mean	Baseline vs Absent	0.18 (0.1, 0.25), p < 0.001 ^s	0.15 (0.06, 0.24), p = 0.015
Apathy	Mean	Incident vs Absent	0.10 (0.03, 0.18), p = 0.029	0.14 (0.05, 0.24), p = 0.015 ^s
Apathy	Slope	Baseline vs Absent	0.04 (0.02, 0.06), p < 0.001 ^s	-0.01 (-0.04, 0.03), p = 0.789
Apathy	Slope	Incident vs Absent	0.03 (0.01, 0.05), p = 0.009	0.01 (-0.03, 0.04), p = 0.789
Depression	Mean	Baseline vs Absent	0.11 (0.05, 0.18), p = 0.009	0.11 (0.02, 0.20), p = 0.048
Depression	Mean	Incident vs Absent	0.04 (-0.03, 0.12), p = 0.39	0.04 (-0.06, 0.13), p = 0.595
Depression	Slope	Baseline vs Absent	0.02 (0, 0.04), p = 0.048	0.01 (-0.02, 0.04), p = 0.623
Depression	Slope	Incident vs Absent	0 (-0.02, 0.02), p = 0.789	0.02 (-0.01, 0.05), p = 0.39
Anxiety	Mean	Baseline vs Absent	0.16 (0.09, 0.23), p < 0.001 ^s	0.19 (0.1, 0.29), p = 0.001^s
Anxiety	Mean	Incident vs Absent	0.14 (0.07, 0.21), p = 0.002^s	0.11 (0.01, 0.20), p = 0.068
Anxiety	Slope	Baseline vs Absent	0.02 (0, 0.04), p = 0.118	-0.01 (-0.05, 0.02), p = 0.665
Anxiety	Slope	Incident vs Absent	0.01 (-0.01, 0.03), p = 0.39	0.01 (-0.02, 0.04), p = 0.682

604	Table 2: Summary of Apathy and	1 Affective Symptom Effects	on Plasma NfL and p-Tau181
-----	--------------------------------	-----------------------------	----------------------------

605 Note: Results are displayed as β (95% confidence interval), p-value adjusted for multiple comparisons.

606 Analyses are corrected for age and gender.

607 **Bolded** indicates statistical significance set at p < 0.05

⁶O8 ^sSurvived sensitivity analysis adding CDR-SB and MMSE as covariates separately

609 NfL = neurofilament light chain, p-tau181 = phosphorylated-tau 181, NPS = neuropsychiatric symptom

- 610
- 611
- 612

613 Table 3: Subgroup analysis of Apathy and Affective Symptom Effects on Plasma NfL and p-Tau181

614 in amyloid positive group only

NPS	Mean or Slope	Comparison Groups	Plasma NfL	Plasma p-tau181
Apathy	Mean	Baseline vs Absent	0.15 (0.07, 0.24), p = 0.001	0.13 (0.03, 0.23), p = 0.015
Apathy	Mean	Incident vs Absent	0.07 (-0.01, 0.16), p = 0.102	0.08 (-0.02, 0.18), p = 0.107
Apathy	Slope	Baseline vs Absent	0.04 (0.02, 0.07), p < 0.001	0.03 (-0.01, 0.07), p = 0.219
Apathy	Slope	Incident vs Absent	0.03 (0.01, 0.05), p = 0.014	0.02 (-0.02, 0.06), p = 0.336
Depression	Mean	Baseline vs Absent	0.14 (0.05, 0.22), p = 0.001	0.12 (0.02, 0.22), p = 0.017
Depression	Mean	Incident vs Absent	0.04 (-0.04, 0.13), p = 0.34	0.01 (-0.10, 0.11), p = 0.912
Depression	Slope	Baseline vs Absent	0.02 (0, 0.04), p = 0.110	0.02 (-0.02, 0.06), p = 0.265
Depression	Slope	Incident vs Absent	0.01 (-0.02, 0.03), p = 0.589	0.01 (-0.02, 0.05), p = 0.454
Anxiety	Mean	Baseline vs Absent	0.13 (0.04, 0.22), p = 0.005	0.08 (-0.03, 0.19), p = 0.153
Anxiety	Mean	Incident vs Absent	0.12 (0.03, 0.21), p = 0.008	0 (-0.10, 0.11), p = 0.967
Anxiety	Slope	Baseline vs Absent	0.03 (0, 0.05), p = 0.058	-0.01 (-0.05, 0.03), p = 0.595
Anxiety	Slope	Incident vs Absent	0.02 (0, 0.03), p = 0.12	0.02 (-0.02, 0.06), p = 0.258

Note: Results are displayed as β (95% confidence interval). Analyses are corrected for age and gender.

616 Amyloid positive status determined by AV45 SUVR > 1.11 during the study.

617 **Bolded** indicates statistical significance set at p < 0.05

618 NfL = neurofilament light chain, p-tau181 = phosphorylated-tau 181, NPS = neuropsychiatric symptom

619

620



Figure 1 – Longitudinal plots of plasma biomarkers for apathy, depression and anxiety in the clinical spectrum of Alzheimer's disease





Significant differences between slopes are represented on the slope, whilst the significant differences between group levels are represented on the right of the plot. Sample sizes for each timepoint are displayed on the table below each lien plot. A. NfL differences between apathy groups, B. p-tau181 differences between apathy groups, C. NfL differences between depression groups, D. p-tau181 differences between depression groups, E. NfL differences between anxiety groups, F. p-tau181 differences between anxiety groups. Sensitivity analyses involved adding CDR-SB and MMSE as separate covariates, and subgroup analysis of amyloid positive participants only. *** = Survived all sensitivity analyses;** NfL = neurofilament light chain, p-tau181 = phosphorylated tau at threonine 181.



Figure 2 - Forest plots of NPS effects on plasma biomarkers

Forest plot summarising the associations between biomarker level and specific neuropsychiatric symptoms. Significant findings were adjusted p-values < 0.05. Sensitivity analyses involved adding CDR-SB and MMSE as separate covariates, and subgroup analysis of amyloid positive participants only. NfL = neurofilament light chain, p-tau181 = phosphorylated tau at threonine 181, NPS = neuropsychiatric symptom